RxDoctor Payments Data

Lindsay Manjarres

Family · North Las Vegas, NVNPI 1154794816

Payments from drug & device makers

$1,943in general payments, 2019–2025

Across 49 payments — averaging $39.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$522
  • Medtronic$421
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$178
  • SPR Therapeutics, Inc$175
  • Boston Scientific$133
  • IBSA Pharma Inc.$124
  • plus $390 from 8 others

What the payments were for

  • Food & beverage$1,943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,943 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$25,224
Medicare patients
131
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant23$30,052
QuliptaAtogepant24$26,641
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen341$19,426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen428$14,224
Lidocaine62$5,176
Oxycodone Hcl197$3,740
Diclofenac Sodium75$3,621
Gabapentin246$2,632
Tizanidine Hcl285$2,557
Pregabalin152$2,174
Cyclobenzaprine Hcl127$1,198
Lidocaine-PrilocaineLidocaine/Prilocaine30$768
Morphine Sulfate ErMorphine Sulfate53$745
Duloxetine Hcl128$744
Tramadol Hcl95$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$90$56,69347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.

Other family in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →